Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug;17(4):739-749.
doi: 10.31616/asj.2022.0377. Epub 2023 Jul 6.

Assessing the Performance of Prognostic Scores in Patients with Spinal Metastases from Lung Cancer Undergoing Non-surgical Treatment

Van Tri Truong  1   2 , Fidaa Al-Shakfa  1 , David Roberge  3 , Giuseppina Laura Masucci  3 , Thi Phuoc Yen Tran  4   5 , Rama Dib  1 , Sung-Joo Yuh  6 , Zhi Wang  1
Affiliations

Assessing the Performance of Prognostic Scores in Patients with Spinal Metastases from Lung Cancer Undergoing Non-surgical Treatment

Van Tri Truong et al. Asian Spine J. 2023 Aug.

Abstract

Study design: Retrospective study.

Purpose: The purpose of this study was to see how well the Tomita score, revised Tokuhashi score, modified Bauer score, Van der Linden score, classic Skeletal Oncology Research Group (SORG) algorithm, SORG nomogram, and New England Spinal Metastasis Score (NESMS) predicted 3-month, 6-month, and 1-year survival of non-surgical lung cancer spinal metastases.

Overview of literature: There has been no study assessing the performance of prognostic scores for non-surgical lung cancer spinal metastases.

Methods: Data analysis was carried out to identify the variables that had a significant impact on survival. For all patients with spinal metastasis from lung cancer who received non-surgical treatment, the Tomita score, revised Tokuhashi score, modified Bauer score, Van der Linden score, classic SORG algorithm, SORG nomogram, and NESMS were calculated. The performance of the scoring systems was assessed by using receiver operating characteristic (ROC) curves at 3 months, 6 months, and 12 months. The predictive accuracy of the scoring systems was quantified using the area under the ROC curve (AUC).

Results: A total of 127 patients are included in the present study. The median survival of the population study was 5.3 months (95% confidence interval [CI], 3.7-9.6 months). Low hemoglobin was associated with shorter survival (hazard ratio [HR], 1.49; 95% CI, 1.00-2.23; p =0.049), while targeted therapy after spinal metastasis was associated with longer survival (HR, 0.34; 95% CI, 0.21-0.51; p <0.001). In the multivariate analysis, targeted therapy was independently associated with longer survival (HR, 0.3; 95% CI, 0.17-0.5; p <0.001). The AUC of the time-dependent ROC curves for the above prognostic scores revealed all of them performed poorly (AUC <0.7).

Conclusions: The seven scoring systems investigated are ineffective at predicting survival in patients with spinal metastasis from lung cancer who are treated non-surgically.

Keywords: Adenocarcinoma; Area under curve; Lung neoplasms; Prognosis; Spinal neoplasms.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1
Fig. 1
The Kaplan-Meier line of the survival of the population.
Fig. 2
Fig. 2
Receiver operating characteristic curve of the prognostic scores at 3 months. NESMS, New England Spinal Metastasis Score; SORG, Skeletal Oncology Research Group.
Fig. 3
Fig. 3
Receiver operating characteristic curve of the prognostic scores at 6 months. NESMS, New England Spinal Metastasis Score; SORG, Skeletal Oncology Research Group.
Fig. 4
Fig. 4
Receiver operating characteristic curve of the prognostic scores at 12 months. NESMS, New England Spinal Metastasis Score; SORG, Skeletal Oncology Research Group.
See this image and copyright information in PMC

References

    1. International Agency for Research on Cancer; World Health Organization . Global Cancer Observatory [Internet] Lyon: International Agency for Research on Cancer; c2022. [cited 2022 Oct 14]. Available from: https://gco.iarc.fr/
    1. Decroisette C, Monnet I, Berard H, et al. Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601) J Thorac Oncol. 2011;6:576–82. - PubMed
    1. Uei H, Tokuhashi Y, Maseda M. Treatment outcome of metastatic spine tumor in lung cancer patients: did the treatments improve their outcomes? Spine (Phila Pa 1976) 2017;42:E1446–51. - PMC - PubMed
    1. Kumar N, Malhotra R, Zaw AS, et al. Evolution in treatment strategy for metastatic spine disease: presently evolving modalities. Eur J Surg Oncol. 2017;43:1784–801. - PubMed
    1. Tomita K, Kawahara N, Kobayashi T, Yoshida A, Murakami H, Akamaru T. Surgical strategy for spinal metastases. Spine (Phila Pa 1976) 2001;26:298–306. - PubMed